Nautilus Biotechnology In... (NAUT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
2.02
0.02 (1.00%)
At close: Jan 24, 2025, 11:40 AM
Company Description
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome.
It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
The company was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology Inc.
Country | United States |
IPO Date | Aug 7, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 161 |
CEO | Sujal M. Patel |
Contact Details
Address: 2701 Eastlake Avenue East Seattle, Washington United States | |
Website | https://www.nautilus.bio |
Stock Details
Ticker Symbol | NAUT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001808805 |
CUSIP Number | 63909J108 |
ISIN Number | US63909J1088 |
Employer ID | 00-0000000 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Sujal M. Patel | Co-Founder, Chief Executive Officer, President, Secretary & Director |
Anna Mowry | Chief Financial Officer & Treasurer |
Gwen E. Weld | Chief People Officer |
Kentaro Suzuki | Chief Marketing Officer |
Chris Blessington | Vice President of Corporate Marketing & Communications |
Dr. Parag Mallick Ph.D. | Co-Founder, Chief Scientist & Director |
Dr. Subra Sankar Ph.D. | Senior Vice President of Product Development |
Matthew B. Murphy ESQ. | General Counsel |
Nick A. Nelson | Chief Business Officer & Senior Vice President of Business Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13D/A | [Amend] Filing |
Oct 29, 2024 | 10-Q | Quarterly Report |
Oct 29, 2024 | 8-K | Current Report |
Sep 25, 2024 | 4 | Filing |
Sep 18, 2024 | 4 | Filing |
Sep 17, 2024 | 4 | Filing |
Sep 17, 2024 | 3 | Filing |
Jul 30, 2024 | 10-Q | Quarterly Report |
Jul 30, 2024 | 8-K | Current Report |
Jun 17, 2024 | 4 | Filing |